CABA
Cabaletta Bio, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.43
−1.42%Next report
Analyst consensus
- Next report date
- Nov 9, 2026
- EPS estimate
- -$0.33
- Revenue estimate
- $1.7M
Latest reported
- Last report date
- Aug 13, 2026
- EPS actual
- -$0.34
- EPS estimate
- -$0.37
- Revenue actual
- —
- Revenue estimate
- $1.7M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 5
- EPS misses (12Q)
- 6
- EPS in line (12Q)
- 1
- Avg surprise (4Q)
- +5.5%
- Revenue beats (12Q)
- —
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $9.50
- PT range
- $3.00 – $16
- Analysts
- 2
1 Buy1 Hold0 Sell
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 9, 2026